News By Wire

Anivive Named Winner at Leading European Innovation Summit

Anivive Lifesciences, a leading pet health company, was recently awarded the top Companion Animal Start-up for the Innovation Showcase at the Animal Health, Nutrition & Technology Innovation Europe summit held in London from March 6-8.

Animal Health, Nutrition & Technology Innovation Europe is the sector’s premier innovation conference. The Innovation Showcase is a unique opportunity where 20 of the most innovative companies are selected amongst 150 peer companies to present in front of the industry’s most influential figures and investors including Partners Group, Bank of America, GHO Capital, Digitalis Ventures, Google Ventures, Rabdan Holding, Stifle and CEOs from the top global animal health companies.

Anivive’s achievement was particularly notable due to its significant advancements in the development of the Valley Fever Vaccine for dogs and its breakthrough Feline Infectious Peritonitis (FIP) treatment.

Dylan Balsz, Anivive founder & CEO commented: “This is Europe’s most influential animal health summit, so to receive this award was an honor and we are very proud that the work we are doing within the pet healthcare sector has been recognized by our industry peers.”

The award highlights the company’s commitment to improving the health and well-being of companion animals worldwide.



Press release information


Image File:

Dylan Balsz at the Animal Health, Nutrition & Technology Innovation Europe summit

Area / Region:

Topics / Tags:

Notes to editors

About Anivive Lifesciences Anivive is a pet health company at the intersection of biotech, AI, software, and veterinary medicine. Focusing on three key therapeutic platforms; Fungal, Oncology, and Infectious Disease, our proprietary software platform accelerates the delivery of new, affordable treatments for various life-threatening diseases in pets.

Media contact

Media contact name:

Thomas Wright

Media contact business / organisation:


Media contact telephone:

001 4243134869

Media contact email:

All done!
Thank you for subscribing.

Email Subscription